Medigen Biotechnology（3176）株式概要メディジェン・バイオテクノロジー社はバイオ医薬品会社で、台湾で新薬・ワクチン、細胞療法、先進核酸検査、ジェネリック医薬品、美容医療、ワクチン関連製品の研究開発に従事している。 詳細3176 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析リスクチェックの結果、3176 、リスクは検出されなかった。すべてのリスクチェックを見る3176 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW473,046 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA473,046 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$33.7584.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-689m4b2016201920222025202620282031Revenue NT$735.4mEarnings NT$132.5mAdvancedSet Fair ValueView all narrativesMedigen Biotechnology Corp. 競合他社TaiGen Biopharmaceuticals HoldingsSymbol: TPEX:4157Market cap: NT$6.3bMycenax BiotechSymbol: TPEX:4726Market cap: NT$5.1bMaxigen BiotechSymbol: TWSE:1783Market cap: NT$3.6bPet Pharm BiotechSymbol: TPEX:7762Market cap: NT$3.0b価格と性能株価の高値、安値、推移の概要Medigen Biotechnology過去の株価現在の株価NT$33.7552週高値NT$43.6052週安値NT$28.00ベータ0.271ヶ月の変化-4.66%3ヶ月変化0.45%1年変化11.02%3年間の変化8.87%5年間の変化-46.51%IPOからの変化76.70%最新ニュースBoard Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. Independent Director Jou-Kou Wang was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 11Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city TaiwanReported Earnings • Nov 13Third quarter 2025 earnings released: NT$0.41 loss per share (vs NT$0.19 loss in 3Q 2024)Third quarter 2025 results: NT$0.41 loss per share (further deteriorated from NT$0.19 loss in 3Q 2024). Revenue: NT$395.7m (down 9.4% from 3Q 2024). Net loss: NT$56.4m (loss widened 110% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.27 loss per share (vs NT$0.086 profit in 2Q 2024)Second quarter 2025 results: NT$0.27 loss per share (down from NT$0.086 profit in 2Q 2024). Revenue: NT$360.8m (up 1.9% from 2Q 2024). Net loss: NT$38.0m (down 418% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.74 (vs NT$0.54 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.74 (up from NT$0.54 loss in 1Q 2024). Revenue: NT$499.4m (up 99% from 1Q 2024). Net income: NT$102.5m (up NT$178.2m from 1Q 2024). Profit margin: 21% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • May 03Medigen Biotechnology Corp. to Report Q1, 2025 Results on May 12, 2025Medigen Biotechnology Corp. announced that they will report Q1, 2025 results on May 12, 2025最新情報をもっと見るRecent updatesBoard Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. Independent Director Jou-Kou Wang was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 11Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city TaiwanReported Earnings • Nov 13Third quarter 2025 earnings released: NT$0.41 loss per share (vs NT$0.19 loss in 3Q 2024)Third quarter 2025 results: NT$0.41 loss per share (further deteriorated from NT$0.19 loss in 3Q 2024). Revenue: NT$395.7m (down 9.4% from 3Q 2024). Net loss: NT$56.4m (loss widened 110% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.27 loss per share (vs NT$0.086 profit in 2Q 2024)Second quarter 2025 results: NT$0.27 loss per share (down from NT$0.086 profit in 2Q 2024). Revenue: NT$360.8m (up 1.9% from 2Q 2024). Net loss: NT$38.0m (down 418% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.74 (vs NT$0.54 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.74 (up from NT$0.54 loss in 1Q 2024). Revenue: NT$499.4m (up 99% from 1Q 2024). Net income: NT$102.5m (up NT$178.2m from 1Q 2024). Profit margin: 21% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • May 03Medigen Biotechnology Corp. to Report Q1, 2025 Results on May 12, 2025Medigen Biotechnology Corp. announced that they will report Q1, 2025 results on May 12, 2025Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.47 loss per share (vs NT$4.03 loss in FY 2023)Full year 2024 results: NT$1.47 loss per share (improved from NT$4.03 loss in FY 2023). Revenue: NT$1.37b (up 19% from FY 2023). Net loss: NT$204.7m (loss narrowed 64% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • Mar 11Medigen Biotechnology Corp., Annual General Meeting, Jun 05, 2025Medigen Biotechnology Corp., Annual General Meeting, Jun 05, 2025. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwanお知らせ • Mar 04Medigen Biotechnology Corporation Announces Resignation of Chieh-Liang Lin as Chief Scientific OfficerMedigen Biotechnology Corporation announced the resignation of Mr. Chieh-Liang Lin from his position as Chief Scientific Officer, effective March 3, 2025. The resignation is due to business adjustments, and Mr. Lin has been transferred to a subsidiary where he will serve as Chief Operating Officer and Chief Technology Officer.お知らせ • Feb 28Medigen Biotechnology Corp. to Report Q4, 2024 Results on Mar 10, 2025Medigen Biotechnology Corp. announced that they will report Q4, 2024 results on Mar 10, 2025Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.34 loss in 3Q 2023)Third quarter 2024 results: NT$0.19 loss per share (improved from NT$0.34 loss in 3Q 2023). Revenue: NT$436.6m (up 4.7% from 3Q 2023). Net loss: NT$26.9m (loss narrowed 43% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Oct 29Medigen Biotechnology Corp. to Report Q3, 2024 Results on Nov 05, 2024Medigen Biotechnology Corp. announced that they will report Q3, 2024 results on Nov 05, 2024Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: NT$0.08 (vs NT$0.70 loss in 2Q 2023)Second quarter 2024 results: EPS: NT$0.08 (up from NT$0.70 loss in 2Q 2023). Revenue: NT$354.1m (up 72% from 2Q 2023). Net income: NT$11.9m (up NT$109.3m from 2Q 2023). Profit margin: 3.4% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Aug 10Medigen Biotechnology Corp. Announces Change of Accounting Officer, Effective September 1, 2024Medigen Biotechnology Corp. announced change of accounting officer. Name, title, and resume of the previous position holder: I-Ju Chen, Medigen accounting officer. Name, title, and resume of the new position holder: Feng-Hua Chen,Medigen financial officer. Effective date: September 1, 2024.お知らせ • Aug 06Medigen Biotechnology Corp. to Report Q2, 2024 Results on Aug 09, 2024Medigen Biotechnology Corp. announced that they will report Q2, 2024 results on Aug 09, 2024お知らせ • Jun 08Medigen Biotechnology Corp. Announces Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang HospitalMedigen Biotechnology Corp. announced Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital. Medigen, in collaboration with Taipei Municipal Wanfang Hospital managed by Taipei Medical University (referred to as Wanfang Hospital), has applied to the Ministry of Health and Welfare (MOHW) on January 22, 2024, for a new version of the Autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the ”Regulations Governing the Application of Specific Medical Examination Technique and Medical Device”. On June 6, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). Details on the approved items in the abovementioned Wanfang Hospital cell therapy project: (1)Type of Cell Therapy: Autologous natural killer cells (NK cells) - Magicell-NK. (2) Indications: Stage IV solid tumors, including Brain cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer. (3) Cell Processing Unit: Medigen’s cell processing unit (4)Validity Period: From June 4, 2024, to February 2, 2026.Reported Earnings • May 19First quarter 2024 earnings released: NT$0.54 loss per share (vs NT$0.68 loss in 1Q 2023)First quarter 2024 results: NT$0.54 loss per share (improved from NT$0.68 loss in 1Q 2023). Revenue: NT$251.3m (up 53% from 1Q 2023). Net loss: NT$75.7m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • May 03Medigen Biotechnology Corp. to Report Q1, 2024 Results on May 10, 2024Medigen Biotechnology Corp. announced that they will report Q1, 2024 results on May 10, 2024Reported Earnings • Mar 17Full year 2023 earnings released: NT$4.03 loss per share (vs NT$4.86 loss in FY 2022)Full year 2023 results: NT$4.03 loss per share (improved from NT$4.86 loss in FY 2022). Revenue: NT$1.16b (up 9.6% from FY 2022). Net loss: NT$561.3m (loss narrowed 17% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Mar 13Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific OfficerMedigen Biotechnology Corp. announced the appointment of Mr. Chieh-Liang Lin, Senior Associate Vice President of Cell Therapy Department of the company, as Chief Scientific Officer. Approved by the Board of Directors on March 11, 2024.お知らせ • Mar 12Medigen Biotechnology Corp., Annual General Meeting, May 28, 2024Medigen Biotechnology Corp., Annual General Meeting, May 28, 2024. Location: 2nd Floor, Building A, No. 19-10,Sanchong Road, Nangang District International Convention Center Taipei City Taiwan Agenda: To consider 2023 business report; to consider audit committee's review of the 2023 annual final accounting books and statements; to consider report on the revision of some provisions of the company's rules of procedure for board meetings; to consider 2023 business report and financial statements; to consider loss of appropriation proposal of the 2023; to consider re-election of all directors of the company; to consider lifting the restrictions on non-competition for newly elected directors and their representatives; and to consider other issues.お知らせ • Mar 01Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK)Medigen Biotechnology Corp. has applied to the Taiwan Food and Drug Administration (TFDA) for Phase I/II clinical trial of allogeneic natural killer cells (Magicell-NK). New drug name or code: Allogeneic natural killer cells (Magicell-NK). Indication: The application of Phase I/II clinical trial of allogeneic natural killer (NK) cells submitted to the Taiwan Food and Drug Administration (TFDA) involves the use of company's proprietary and independently developed allogeneic natural killer cell expansion technology, Magicell-NK. This technology utilizes blood from donors, which is cultured, activated, and expanded ex vivo to prepare natural killer cell products. These products are then administered back into the patients and will be used as adjuvant therapy post-surgery, in combination with chemotherapy, for pancreatic ductal adenocarcitnoma (PDA) or bile duct cancer patients, aiming to prevent recurrence and increase survival time. Planned development stages: Phase I/II clinical trial. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): Submitted an application for Phase I/II clinical trial to TFDA. Accumulated investment expenditure incurred: Due to considerations of commercial strategy, disclosure is temporarily withheld. Upcoming development plan: Phase I/II clinical trial will commence upon obtaining approval from the TFDA and the Institutional Review Board (IRB). Estimated Completion Time: Expected to be completed in 2029, the actual schedule will be adjusted according to the progress of execution. Expected Obligations: company will bear the expenses related to clinical trials and related registration fees.お知らせ • Jan 12the Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi HospitalMedigen Biotechnology Corporation in collaboration with Taichung Tzu Chi Hospital applied for the Autologous Gamma-Delta T (Magicell-GDT) cell therapy project. On January 11, 2024, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). In accordance with the regulations of the Regulations Governing the Application of Specific Medical examination technique and Medical Device, the Magicell-GDT cells produced at Medigen's Cell Processing Unit can be used for treating stage IV solid tumors at Taichung Tzu Chi hospital. Countermeasures: The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare .Any other matters that need to be specified: (1) Details on the approved items in the abovementioned Taichung Tzu Chi Hospital cell therapy project: A.Type of cell therapy: Autologous Gamma-Delta T cell (Magicell-GDT) B.Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, colorectal cancer C.Cell processing unit: Medigen’s cell processing unit D. Approval period: From January 9, 2024 to February 2, 2026 (2) The manufacturing technology of this approved Gamma-Delta T cell is exclusively licensed from the Japanese listed company MEDINET Co. Ltd. (please see Medigen’s announcement released on 7th October, 2019).New Risk • Oct 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.3% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).New Risk • Aug 13New major risk - Revenue and earnings growthEarnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 12Second quarter 2023 earnings released: NT$0.70 loss per share (vs NT$0.88 loss in 2Q 2022)Second quarter 2023 results: NT$0.70 loss per share (improved from NT$0.88 loss in 2Q 2022). Revenue: NT$205.6m (up 7.3% from 2Q 2022). Net loss: NT$97.3m (loss narrowed 21% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 23% per year.Reported Earnings • Nov 19Third quarter 2022 earnings released: NT$0.84 loss per share (vs NT$0.46 profit in 3Q 2021)Third quarter 2022 results: NT$0.84 loss per share (down from NT$0.46 profit in 3Q 2021). Revenue: NT$176.0m (down 87% from 3Q 2021). Net loss: NT$116.2m (down 283% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 15Second quarter 2022 earnings released: NT$0.88 loss per share (vs NT$0.93 loss in 2Q 2021)Second quarter 2022 results: NT$0.88 loss per share (up from NT$0.93 loss in 2Q 2021). Revenue: NT$191.6m (up 9.5% from 2Q 2021). Net loss: NT$122.8m (loss narrowed 5.0% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2022 earnings released: NT$0.59 loss per share (vs NT$0.46 loss in 1Q 2021)First quarter 2022 results: NT$0.59 loss per share (down from NT$0.46 loss in 1Q 2021). Revenue: NT$484.7m (up 161% from 1Q 2021). Net loss: NT$81.7m (loss widened 28% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 01Full year 2021 earnings released: NT$0.38 loss per share (vs NT$2.43 loss in FY 2020)Full year 2021 results: NT$0.38 loss per share (up from NT$2.43 loss in FY 2020). Revenue: NT$3.92b (up NT$3.31b from FY 2020). Net loss: NT$52.6m (loss narrowed 84% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.80 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$1.39b (up NT$1.23b from 3Q 2020). Net income: NT$63.6m (up NT$174.2m from 3Q 2020). Profit margin: 4.6% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year.Reported Earnings • Aug 15Second quarter 2021 earnings released: NT$0.93 loss per share (vs NT$0.65 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: NT$174.9m (up 25% from 2Q 2020). Net loss: NT$129.3m (loss widened 43% from 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.Reported Earnings • May 15First quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.51 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$185.7m (up 42% from 1Q 2020). Net loss: NT$64.1m (loss narrowed 9.1% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.分析記事 • Apr 13Is Medigen Biotechnology (GTSM:3176) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 31Full year 2020 earnings released: NT$2.43 loss per share (vs NT$2.84 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$615.5m (up 11% from FY 2019). Net loss: NT$337.9m (loss narrowed 14% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 20New 90-day high: NT$66.60The company is up 9.0% from its price of NT$61.00 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period.分析記事 • Feb 19Medigen Biotechnology (GTSM:3176) Shareholders Have Enjoyed A 83% Share Price GainBy buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...Is New 90 Day High Low • Jan 27New 90-day low: NT$49.30The company is down 13% from its price of NT$56.70 on 30 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: NT$55.40The company is down 12% from its price of NT$63.10 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.分析記事 • Dec 29Does Medigen Biotechnology (GTSM:3176) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.79 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: NT$154.1m (up 40% from 3Q 2019). Net loss: NT$110.6m (loss widened 28% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 29New 90-day low: NT$57.50The company is down 26% from its price of NT$77.50 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: NT$63.10The company is down 27% from its price of NT$86.70 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period.Is New 90 Day High Low • Sep 25New 90-day low: NT$65.20The company is down 18% from its price of NT$79.50 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.お知らせ • Sep 23TBG Biotechnology Corp. Enters Distribution Agreement with Medigen Biotechnology CorpTBG Diagnostics Limited announces that its wholly owned subsidiary TBG Biotechnology Corp. entered into a distribution agreement with Medigen Biotechnology Corp. to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit (Colloidal Gold) and Nucleic Acid Test Kit . The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen.株主還元3176TW BiotechsTW 市場7D0.1%14.5%3.6%1Y11.0%98.8%86.0%株主還元を見る業界別リターン: 3176過去 1 年間で98.8 % の収益を上げたTW Biotechs業界を下回りました。リターン対市場: 3176は、過去 1 年間で86 % のリターンを上げたTW市場を下回りました。価格変動Is 3176's price volatile compared to industry and market?3176 volatility3176 Average Weekly Movement7.7%Biotechs Industry Average Movement6.0%Market Average Movement6.4%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.7%安定した株価: 3176 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 3176の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1990n/aShun-Lang Changwww.medigen.com.twバイオ医薬品会社であるメディジェン・バイオテクノロジー社は、台湾で新薬・ワクチン、細胞療法、先進核酸検査、ジェネリック医薬品、美容医療、ワクチン関連製品の研究開発に従事。ナチュラルキラー細胞であるMAGICELL-NKやT細胞であるMAGICELL-GDTなどの細胞療法を提供している。また、OBP-301を開発しており、日本では食道がん患者を対象とした併用療法の第I相臨床試験を終了し、日本では食道がん患者を対象とした免疫チェックポイント阻害薬（ICI）との併用療法の第I相臨床試験中であり、米国では頭頸部がんおよび胃がん患者を対象としたICIとの併用療法の第II相臨床試験中である。メディジェン・バイオテクノロジー社は1999年に設立され、本社は台湾の台北市にある。もっと見るMedigen Biotechnology Corp. 基礎のまとめMedigen Biotechnology の収益と売上を時価総額と比較するとどうか。3176 基礎統計学時価総額NT$4.70b収益（TTM）-NT$264.40m売上高(TTM)NT$1.34b3.5xP/Sレシオ-17.8xPER（株価収益率3176 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計3176 損益計算書（TTM）収益NT$1.34b売上原価NT$656.76m売上総利益NT$687.87mその他の費用NT$952.27m収益-NT$264.40m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.90グロス・マージン51.16%純利益率-19.66%有利子負債／自己資本比率27.8%3176 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/14 05:58終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medigen Biotechnology Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Yijun ChenSinoPac Securities Investment Service
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. Independent Director Jou-Kou Wang was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 11Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan
Reported Earnings • Nov 13Third quarter 2025 earnings released: NT$0.41 loss per share (vs NT$0.19 loss in 3Q 2024)Third quarter 2025 results: NT$0.41 loss per share (further deteriorated from NT$0.19 loss in 3Q 2024). Revenue: NT$395.7m (down 9.4% from 3Q 2024). Net loss: NT$56.4m (loss widened 110% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.27 loss per share (vs NT$0.086 profit in 2Q 2024)Second quarter 2025 results: NT$0.27 loss per share (down from NT$0.086 profit in 2Q 2024). Revenue: NT$360.8m (up 1.9% from 2Q 2024). Net loss: NT$38.0m (down 418% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.74 (vs NT$0.54 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.74 (up from NT$0.54 loss in 1Q 2024). Revenue: NT$499.4m (up 99% from 1Q 2024). Net income: NT$102.5m (up NT$178.2m from 1Q 2024). Profit margin: 21% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • May 03Medigen Biotechnology Corp. to Report Q1, 2025 Results on May 12, 2025Medigen Biotechnology Corp. announced that they will report Q1, 2025 results on May 12, 2025
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. Independent Director Jou-Kou Wang was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 11Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan
Reported Earnings • Nov 13Third quarter 2025 earnings released: NT$0.41 loss per share (vs NT$0.19 loss in 3Q 2024)Third quarter 2025 results: NT$0.41 loss per share (further deteriorated from NT$0.19 loss in 3Q 2024). Revenue: NT$395.7m (down 9.4% from 3Q 2024). Net loss: NT$56.4m (loss widened 110% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.27 loss per share (vs NT$0.086 profit in 2Q 2024)Second quarter 2025 results: NT$0.27 loss per share (down from NT$0.086 profit in 2Q 2024). Revenue: NT$360.8m (up 1.9% from 2Q 2024). Net loss: NT$38.0m (down 418% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.74 (vs NT$0.54 loss in 1Q 2024)First quarter 2025 results: EPS: NT$0.74 (up from NT$0.54 loss in 1Q 2024). Revenue: NT$499.4m (up 99% from 1Q 2024). Net income: NT$102.5m (up NT$178.2m from 1Q 2024). Profit margin: 21% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • May 03Medigen Biotechnology Corp. to Report Q1, 2025 Results on May 12, 2025Medigen Biotechnology Corp. announced that they will report Q1, 2025 results on May 12, 2025
Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.47 loss per share (vs NT$4.03 loss in FY 2023)Full year 2024 results: NT$1.47 loss per share (improved from NT$4.03 loss in FY 2023). Revenue: NT$1.37b (up 19% from FY 2023). Net loss: NT$204.7m (loss narrowed 64% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 11Medigen Biotechnology Corp., Annual General Meeting, Jun 05, 2025Medigen Biotechnology Corp., Annual General Meeting, Jun 05, 2025. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan
お知らせ • Mar 04Medigen Biotechnology Corporation Announces Resignation of Chieh-Liang Lin as Chief Scientific OfficerMedigen Biotechnology Corporation announced the resignation of Mr. Chieh-Liang Lin from his position as Chief Scientific Officer, effective March 3, 2025. The resignation is due to business adjustments, and Mr. Lin has been transferred to a subsidiary where he will serve as Chief Operating Officer and Chief Technology Officer.
お知らせ • Feb 28Medigen Biotechnology Corp. to Report Q4, 2024 Results on Mar 10, 2025Medigen Biotechnology Corp. announced that they will report Q4, 2024 results on Mar 10, 2025
Reported Earnings • Nov 19Third quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.34 loss in 3Q 2023)Third quarter 2024 results: NT$0.19 loss per share (improved from NT$0.34 loss in 3Q 2023). Revenue: NT$436.6m (up 4.7% from 3Q 2023). Net loss: NT$26.9m (loss narrowed 43% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 29Medigen Biotechnology Corp. to Report Q3, 2024 Results on Nov 05, 2024Medigen Biotechnology Corp. announced that they will report Q3, 2024 results on Nov 05, 2024
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: NT$0.08 (vs NT$0.70 loss in 2Q 2023)Second quarter 2024 results: EPS: NT$0.08 (up from NT$0.70 loss in 2Q 2023). Revenue: NT$354.1m (up 72% from 2Q 2023). Net income: NT$11.9m (up NT$109.3m from 2Q 2023). Profit margin: 3.4% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 10Medigen Biotechnology Corp. Announces Change of Accounting Officer, Effective September 1, 2024Medigen Biotechnology Corp. announced change of accounting officer. Name, title, and resume of the previous position holder: I-Ju Chen, Medigen accounting officer. Name, title, and resume of the new position holder: Feng-Hua Chen,Medigen financial officer. Effective date: September 1, 2024.
お知らせ • Aug 06Medigen Biotechnology Corp. to Report Q2, 2024 Results on Aug 09, 2024Medigen Biotechnology Corp. announced that they will report Q2, 2024 results on Aug 09, 2024
お知らせ • Jun 08Medigen Biotechnology Corp. Announces Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang HospitalMedigen Biotechnology Corp. announced Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital. Medigen, in collaboration with Taipei Municipal Wanfang Hospital managed by Taipei Medical University (referred to as Wanfang Hospital), has applied to the Ministry of Health and Welfare (MOHW) on January 22, 2024, for a new version of the Autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the ”Regulations Governing the Application of Specific Medical Examination Technique and Medical Device”. On June 6, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). Details on the approved items in the abovementioned Wanfang Hospital cell therapy project: (1)Type of Cell Therapy: Autologous natural killer cells (NK cells) - Magicell-NK. (2) Indications: Stage IV solid tumors, including Brain cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer. (3) Cell Processing Unit: Medigen’s cell processing unit (4)Validity Period: From June 4, 2024, to February 2, 2026.
Reported Earnings • May 19First quarter 2024 earnings released: NT$0.54 loss per share (vs NT$0.68 loss in 1Q 2023)First quarter 2024 results: NT$0.54 loss per share (improved from NT$0.68 loss in 1Q 2023). Revenue: NT$251.3m (up 53% from 1Q 2023). Net loss: NT$75.7m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • May 03Medigen Biotechnology Corp. to Report Q1, 2024 Results on May 10, 2024Medigen Biotechnology Corp. announced that they will report Q1, 2024 results on May 10, 2024
Reported Earnings • Mar 17Full year 2023 earnings released: NT$4.03 loss per share (vs NT$4.86 loss in FY 2022)Full year 2023 results: NT$4.03 loss per share (improved from NT$4.86 loss in FY 2022). Revenue: NT$1.16b (up 9.6% from FY 2022). Net loss: NT$561.3m (loss narrowed 17% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 13Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific OfficerMedigen Biotechnology Corp. announced the appointment of Mr. Chieh-Liang Lin, Senior Associate Vice President of Cell Therapy Department of the company, as Chief Scientific Officer. Approved by the Board of Directors on March 11, 2024.
お知らせ • Mar 12Medigen Biotechnology Corp., Annual General Meeting, May 28, 2024Medigen Biotechnology Corp., Annual General Meeting, May 28, 2024. Location: 2nd Floor, Building A, No. 19-10,Sanchong Road, Nangang District International Convention Center Taipei City Taiwan Agenda: To consider 2023 business report; to consider audit committee's review of the 2023 annual final accounting books and statements; to consider report on the revision of some provisions of the company's rules of procedure for board meetings; to consider 2023 business report and financial statements; to consider loss of appropriation proposal of the 2023; to consider re-election of all directors of the company; to consider lifting the restrictions on non-competition for newly elected directors and their representatives; and to consider other issues.
お知らせ • Mar 01Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK)Medigen Biotechnology Corp. has applied to the Taiwan Food and Drug Administration (TFDA) for Phase I/II clinical trial of allogeneic natural killer cells (Magicell-NK). New drug name or code: Allogeneic natural killer cells (Magicell-NK). Indication: The application of Phase I/II clinical trial of allogeneic natural killer (NK) cells submitted to the Taiwan Food and Drug Administration (TFDA) involves the use of company's proprietary and independently developed allogeneic natural killer cell expansion technology, Magicell-NK. This technology utilizes blood from donors, which is cultured, activated, and expanded ex vivo to prepare natural killer cell products. These products are then administered back into the patients and will be used as adjuvant therapy post-surgery, in combination with chemotherapy, for pancreatic ductal adenocarcitnoma (PDA) or bile duct cancer patients, aiming to prevent recurrence and increase survival time. Planned development stages: Phase I/II clinical trial. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): Submitted an application for Phase I/II clinical trial to TFDA. Accumulated investment expenditure incurred: Due to considerations of commercial strategy, disclosure is temporarily withheld. Upcoming development plan: Phase I/II clinical trial will commence upon obtaining approval from the TFDA and the Institutional Review Board (IRB). Estimated Completion Time: Expected to be completed in 2029, the actual schedule will be adjusted according to the progress of execution. Expected Obligations: company will bear the expenses related to clinical trials and related registration fees.
お知らせ • Jan 12the Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi HospitalMedigen Biotechnology Corporation in collaboration with Taichung Tzu Chi Hospital applied for the Autologous Gamma-Delta T (Magicell-GDT) cell therapy project. On January 11, 2024, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). In accordance with the regulations of the Regulations Governing the Application of Specific Medical examination technique and Medical Device, the Magicell-GDT cells produced at Medigen's Cell Processing Unit can be used for treating stage IV solid tumors at Taichung Tzu Chi hospital. Countermeasures: The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare .Any other matters that need to be specified: (1) Details on the approved items in the abovementioned Taichung Tzu Chi Hospital cell therapy project: A.Type of cell therapy: Autologous Gamma-Delta T cell (Magicell-GDT) B.Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, colorectal cancer C.Cell processing unit: Medigen’s cell processing unit D. Approval period: From January 9, 2024 to February 2, 2026 (2) The manufacturing technology of this approved Gamma-Delta T cell is exclusively licensed from the Japanese listed company MEDINET Co. Ltd. (please see Medigen’s announcement released on 7th October, 2019).
New Risk • Oct 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.3% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
New Risk • Aug 13New major risk - Revenue and earnings growthEarnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 12Second quarter 2023 earnings released: NT$0.70 loss per share (vs NT$0.88 loss in 2Q 2022)Second quarter 2023 results: NT$0.70 loss per share (improved from NT$0.88 loss in 2Q 2022). Revenue: NT$205.6m (up 7.3% from 2Q 2022). Net loss: NT$97.3m (loss narrowed 21% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 23% per year.
Reported Earnings • Nov 19Third quarter 2022 earnings released: NT$0.84 loss per share (vs NT$0.46 profit in 3Q 2021)Third quarter 2022 results: NT$0.84 loss per share (down from NT$0.46 profit in 3Q 2021). Revenue: NT$176.0m (down 87% from 3Q 2021). Net loss: NT$116.2m (down 283% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 15Second quarter 2022 earnings released: NT$0.88 loss per share (vs NT$0.93 loss in 2Q 2021)Second quarter 2022 results: NT$0.88 loss per share (up from NT$0.93 loss in 2Q 2021). Revenue: NT$191.6m (up 9.5% from 2Q 2021). Net loss: NT$122.8m (loss narrowed 5.0% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2022 earnings released: NT$0.59 loss per share (vs NT$0.46 loss in 1Q 2021)First quarter 2022 results: NT$0.59 loss per share (down from NT$0.46 loss in 1Q 2021). Revenue: NT$484.7m (up 161% from 1Q 2021). Net loss: NT$81.7m (loss widened 28% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 01Full year 2021 earnings released: NT$0.38 loss per share (vs NT$2.43 loss in FY 2020)Full year 2021 results: NT$0.38 loss per share (up from NT$2.43 loss in FY 2020). Revenue: NT$3.92b (up NT$3.31b from FY 2020). Net loss: NT$52.6m (loss narrowed 84% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.80 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$1.39b (up NT$1.23b from 3Q 2020). Net income: NT$63.6m (up NT$174.2m from 3Q 2020). Profit margin: 4.6% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year.
Reported Earnings • Aug 15Second quarter 2021 earnings released: NT$0.93 loss per share (vs NT$0.65 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: NT$174.9m (up 25% from 2Q 2020). Net loss: NT$129.3m (loss widened 43% from 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
Reported Earnings • May 15First quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.51 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$185.7m (up 42% from 1Q 2020). Net loss: NT$64.1m (loss narrowed 9.1% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
分析記事 • Apr 13Is Medigen Biotechnology (GTSM:3176) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 31Full year 2020 earnings released: NT$2.43 loss per share (vs NT$2.84 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$615.5m (up 11% from FY 2019). Net loss: NT$337.9m (loss narrowed 14% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 20New 90-day high: NT$66.60The company is up 9.0% from its price of NT$61.00 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period.
分析記事 • Feb 19Medigen Biotechnology (GTSM:3176) Shareholders Have Enjoyed A 83% Share Price GainBy buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...
Is New 90 Day High Low • Jan 27New 90-day low: NT$49.30The company is down 13% from its price of NT$56.70 on 30 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: NT$55.40The company is down 12% from its price of NT$63.10 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
分析記事 • Dec 29Does Medigen Biotechnology (GTSM:3176) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.79 loss per shareThe company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: NT$154.1m (up 40% from 3Q 2019). Net loss: NT$110.6m (loss widened 28% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 29New 90-day low: NT$57.50The company is down 26% from its price of NT$77.50 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: NT$63.10The company is down 27% from its price of NT$86.70 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period.
Is New 90 Day High Low • Sep 25New 90-day low: NT$65.20The company is down 18% from its price of NT$79.50 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
お知らせ • Sep 23TBG Biotechnology Corp. Enters Distribution Agreement with Medigen Biotechnology CorpTBG Diagnostics Limited announces that its wholly owned subsidiary TBG Biotechnology Corp. entered into a distribution agreement with Medigen Biotechnology Corp. to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit (Colloidal Gold) and Nucleic Acid Test Kit . The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen.
